NASDAQ:NKTR - Nektar Therapeutics Stock Price, Forecast & News

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.17. The biopharmaceutical company had revenue of $29.22 million for the quarter, compared to analyst estimates of $26.42 million. Nektar Therapeutics had a negative net margin of 352.83% and a negative return on equity of 26.60%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.56) EPS. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Nektar Therapeutics.

14 analysts have issued twelve-month price targets for Nektar Therapeutics' stock. Their forecasts range from $16.00 to $43.00. On average, they expect Nektar Therapeutics' share price to reach $30.46 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

News headlines about NKTR stock have trended neutral this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nektar Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the near future. View News Stories for Nektar Therapeutics.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Hawkins (HWKN), Gilead Sciences (GILD), Incyte (INCY), Netflix (NFLX), Intel (INTC), AT&T (T) and Puma Biotechnology (PBYI).

Nektar Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.63%), New York State Teachers Retirement System (0.12%), Tocqueville Asset Management L.P. (0.11%), Coronation Fund Managers Ltd. (0.06%), Empire Life Investments Inc. (0.06%) and Commerzbank Aktiengesellschaft FI (0.04%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Zurcher Kantonalbank Zurich Cantonalbank , Tocqueville Asset Management L.P., Exane Derivatives, New York State Teachers Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

NKTR stock was bought by a variety of institutional investors in the last quarter, including Coronation Fund Managers Ltd., Louisiana State Employees Retirement System, DNB Asset Management AS, Private Asset Management Inc., State of Michigan Retirement System, Commerzbank Aktiengesellschaft FI, NEXT Financial Group Inc and Nisa Investment Advisors LLC. View Insider Buying and Selling for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $21.13.

Nektar Therapeutics has a market capitalization of $3.72 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.

The official website for Nektar Therapeutics is http://www.nektar.com/.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]